Compare FTEL & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEL | BGLC |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Australia | Malaysia |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 10.1M |
| IPO Year | 2022 | 2019 |
| Metric | FTEL | BGLC |
|---|---|---|
| Price | $1.81 | $2.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 26.9K | 8.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 101.27% | N/A |
| EPS Growth | N/A | ★ 45.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,510,646.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.23 |
| 52 Week High | $15.79 | $15.19 |
| Indicator | FTEL | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 36.17 |
| Support Level | $1.82 | $1.92 |
| Resistance Level | $2.00 | $2.73 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 84.83 | 11.48 |
Fitell Corp conducts its primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiary, serving personal training studios and commercial gyms. Its product coverage includes four proprietary brands: Muscle Motion for strength-training equipment, Rapid Motion with a focus on commercial items, FleetX for cardio equipment, and Harison for cardio, strength, recovery, and conditioning products. The Company operates in one segment, trading gym equipment, and also provides licensing services and gym equipment to overseas gym studios. Majority of its business is conducted in Australia via its e-commerce platform and third-party sites, with maximum revenue earned from retail.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.